You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽隆藥業(002898.SZ)子公司獲得注射用替加環素藥品註冊批件
格隆匯 12-26 11:56

格隆匯12月26日丨賽隆藥業(002898.SZ)公告,珠海賽隆藥業股份有限公司(以下簡稱“公司”)全資子公司湖南賽隆藥業有限公司於近日獲得國家藥品監督管理局核准簽發的注射用替加環素《藥品註冊批件》,現將相關情況公告如下:

藥品名稱:注射用替加環素;藥品批件號:2019S00661;註冊分類:原化學藥品第6類藥品;批准文號:國藥準字H20193363;藥品批准文號有效期:至2024年12月15日。

注射用替加環素為抗感染藥物,主要適用於18歲及以上患者在下列情況下由特定細菌的敏感菌株所致的感染,包括:複雜性腹腔內感染、複雜性皮膚和皮膚軟組織感染、社區獲得性細菌性肺炎。對於無其他藥物可用的感染,經有經驗的感染科醫生或臨牀醫生討論後,本品也適用於治療8歲及以上兒童患者由特定細菌的敏感菌株所致感染,包括複雜性腹腔內感染、複雜性皮膚和皮膚軟組織感染。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account